Jasper Therapeutics(US:JSPR) Globenewswire·2025-10-23 00:40Core Viewpoint - Jasper Therapeutics, a clinical-stage biotechnology company, is facing a class action lawsuit due to allegations of misleading investors about the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper failed to disclose critical information regarding its manufacturing processes, specifically that it lacked the necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations [2]. - This failure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including briquilimab [2]. - The situation heightened the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects, as well as briquilimab's clinical and commercial potential [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3].